STAT+: FDA wants to exclude weight loss drugs from a compounding list

FDA moves to remove semaglutide, tirzepatide, and liraglutide from its 503B compounding list, saying there's no shortage of GLP-1 drugs from Novo Nordisk and Eli Lilly.
Source
Stat News
Opens original article in a new tab



